Is diltiazem safe to use during pregnancy?

Diltiazem Use in Pregnancy

Diltiazem can be used during pregnancy when the potential maternal benefit justifies the potential fetal risk, but it is not a first-line agent and should be reserved for situations where preferred alternatives are ineffective or contraindicated.

Safety Profile and FDA Classification

The FDA drug label clearly states that diltiazem is classified as FDA Pregnancy Category C 1. Animal studies have demonstrated embryo and fetal lethality at doses 5-10 times the human therapeutic dose, with skeletal abnormalities reported in some studies. At doses 20 times the human dose, there was increased incidence of stillbirths and reduced pup weights 1. Critically, there are no well-controlled studies in pregnant women, making the safety profile uncertain.

Clinical Guidelines and Positioning

For Cardiac Arrhythmias

According to the 2015 ACC/AHA/HRS guidelines for supraventricular tachycardia management, diltiazem receives limited support for use in pregnancy 2. The guidelines note that:

• Reports on diltiazem use for acute SVT termination in pregnancy are more limited than for verapamil, yet similar effects are expected 2
• Diltiazem is not explicitly recommended in the guideline hierarchy for pregnant patients with SVT
• Beta-blockers are considered first-line for arrhythmias in pregnancy due to extensive safety data 2
• Verapamil (another calcium channel blocker) receives only a Class IIb recommendation (may be reasonable) when adenosine and beta-blockers fail 2

The 2015 ESC guidelines on ventricular arrhythmias classify diltiazem as FDA Category C, noting that "potential benefits outweigh the risk" but placing it lower in the treatment hierarchy 3.

For Rate Control in Atrial Fibrillation

The 2021 Canadian Cardiovascular Society guidelines suggest that IV diltiazem can be considered for ventricular rate control in narrow complex tachycardia with structural heart disease during pregnancy, but only after vagal maneuvers and/or IV adenosine 4.

For Hypertension

Diltiazem is notably absent from hypertension management guidelines for pregnancy. The 2020 ESC position paper on peripartum hypertension management does not include diltiazem in its recommended treatment algorithms 5. The 2011 ESC guidelines on cardiovascular diseases during pregnancy similarly do not recommend diltiazem for hypertension management 6. The 2003 expert consensus document explicitly lists calcium channel blockers (mainly nifedipine) but notes concerns about rapid blood pressure reduction causing maternal and fetal complications 7.

Limited Clinical Experience

The available research evidence is sparse:

• One small retrospective study (n=7) suggested diltiazem may decrease proteinuria in pregnant women with chronic renal disease 8
• A 1993 report noted diltiazem showed "excellent tocolytic efficacy" but this has not been widely adopted 9
• A 1992 French review recommended avoiding diltiazem due to harmful adverse effects on the fetus 10
• Animal pharmacokinetic studies show diltiazem crosses the placenta easily, reaching fetal blood concentrations equivalent to maternal levels 11

Clinical Decision Algorithm

When considering diltiazem in pregnancy:

1. First, exhaust preferred alternatives:

   • For SVT: Adenosine, then beta-blockers (metoprolol/propranolol)
   • For rate control in AF: Beta-blockers first
   • For hypertension: Methyldopa, labetalol, or nifedipine (not diltiazem)

2. If diltiazem is being considered:

   • Document why first-line agents failed or are contraindicated
   • Ensure the maternal condition is severe enough to justify uncertain fetal risk
   • Use the lowest effective dose
   • Avoid use in the first trimester when possible (highest teratogenic risk period)

3. Monitor closely for:

   • Maternal hypotension (can compromise uteroplacental perfusion)
   • Fetal heart rate abnormalities
   • Signs of fetal distress

4. Counsel the patient that:

   • Animal studies show potential harm at high doses
   • Human safety data are limited
   • Alternative agents with better safety profiles exist

Key Caveats

• The absence of diltiazem from hypertension guidelines is notable – other calcium channel blockers (nifedipine) are preferred when this drug class is needed
• The limited clinical reports compared to verapamil suggest less clinical experience and confidence in its use
• One older source explicitly recommended avoiding diltiazem in pregnancy due to fetal concerns 10, though this has not been universally adopted
• The FDA label's requirement to use "only if the potential benefit justifies the potential risk" is a clear signal of uncertainty 1

In practice, diltiazem should be considered a second- or third-line option in pregnancy, reserved for specific cardiac indications when better-studied alternatives have failed.